Daiichi Sankyo and Eli Lilly have submitted a NDA to the FDA for prasugrel, an oral antiplatelet agent initially in development for the treatment of patients with acute coronary syndrome (ACS) who are managed with percutaneous coronary intervention (PCI), including coronary stenting. If approved, the drug will be marketed as Effient in the U.S. It is seen as a key competitor for Plavix, the antiplatelet drug marketed by Sanofi-Aventis and Bristol-Myers Squibb.     The NDA is based on data fro...